377 related articles for article (PubMed ID: 25954623)
21. Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature.
Genitsch V; Novotny A; Seiler CA; Kröll D; Walch A; Langer R
Front Oncol; 2015; 5():73. PubMed ID: 25859432
[TBL] [Abstract][Full Text] [Related]
22. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
[TBL] [Abstract][Full Text] [Related]
23. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer.
Gullo I; Grillo F; Molinaro L; Fassan M; De Silvestri A; Tinelli C; Rugge M; Fiocca R; Mastracci L
Endosc Int Open; 2015 Apr; 3(2):E165-70. PubMed ID: 26135662
[TBL] [Abstract][Full Text] [Related]
24. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
[TBL] [Abstract][Full Text] [Related]
25. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature.
de la Fouchardiere C; Decoster L; Samalin E; Terret C; Kenis C; Droz JP; Coutzac C; Smyth E
Cancer Treat Rev; 2021 Nov; 100():102289. PubMed ID: 34583303
[TBL] [Abstract][Full Text] [Related]
26. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
Grávalos C; Gómez-Martín C; Rivera F; Alés I; Queralt B; Márquez A; Jiménez U; Alonso V; García-Carbonero R; Sastre J; Colomer R; Cortés-Funes H; Jimeno A
Clin Transl Oncol; 2011 Mar; 13(3):179-84. PubMed ID: 21421462
[TBL] [Abstract][Full Text] [Related]
28. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
Müller V; Clemens M; Jassem J; Al-Sakaff N; Auclair P; Nüesch E; Holloway D; Shing M; Bang YJ
BMC Cancer; 2018 Mar; 18(1):295. PubMed ID: 29544445
[TBL] [Abstract][Full Text] [Related]
29. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.
van Dekken H; Geelen E; Dinjens WN; Wijnhoven BP; Tilanus HW; Tanke HJ; Rosenberg C
Cancer Res; 1999 Feb; 59(3):748-52. PubMed ID: 9973227
[TBL] [Abstract][Full Text] [Related]
30. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
31. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
32. HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma.
Raj N; Verma D; Kumar A; Rai P; Rao RN
Discoveries (Craiova); 2018 Dec; 6(4):e83. PubMed ID: 32309603
[No Abstract] [Full Text] [Related]
33. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
[TBL] [Abstract][Full Text] [Related]
34. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
Boers JE; Meeuwissen H; Methorst N
Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
[TBL] [Abstract][Full Text] [Related]
35. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
[TBL] [Abstract][Full Text] [Related]
36. HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma.
Rima FA; Hussain M; Haque N; Dewan RK; Rahman N; Jinnah MA; Jeba R; Chowdhury F
Mymensingh Med J; 2017 Apr; 26(2):372-379. PubMed ID: 28588175
[TBL] [Abstract][Full Text] [Related]
37. The outcomes of esophageal and gastric cancer treatments in a retrospective study, single center experience.
Alimoghaddam K; Jalali A; Aliabadi LS; Ghaffari F; Maheri R; Eini E; Mashhadireza M; Mousavi SA; Bahar B; Jahani M; Ghavamzadeh A
Int J Hematol Oncol Stem Cell Res; 2014; 8(2):9-13. PubMed ID: 24800033
[TBL] [Abstract][Full Text] [Related]
38. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study.
Watson S; Validire P; Cervera P; Zorkani N; Scriva A; Lemay F; Tournigand C; Perniceni T; Garcia ML; Bennamoun M; Paye F; Louvet C
Ann Oncol; 2013 Dec; 24(12):3035-9. PubMed ID: 24114855
[TBL] [Abstract][Full Text] [Related]
39. Human epidermal growth factor receptor 2 expression in gastric carcinoma and its association with histopathological parameters in Indian population.
Gupta P; Rao S; Bhalla S
Indian J Cancer; 2016; 53(4):505-511. PubMed ID: 28485339
[TBL] [Abstract][Full Text] [Related]
40. EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.
Petrini I; Lencioni M; Vasile E; Fornaro L; Belluomini L; Pasquini G; Ginocchi L; Caparello C; Musettini G; Vivaldi C; Caponi S; Ricci S; Proietti A; Fontanini G; Naccarato AG; Nardini V; Santi S; Falcone A
Cancer Biomark; 2018 Feb; 21(3):731-741. PubMed ID: 29278885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
